Biotech Values

[DewDiligence]

MRNA PR says bivalent booster offers some protection against the BQ.1.1 emerging strain—but it doesn’t say how much:

https://investors.modernatx.com/news/news-details/2022/Modernas-BA.4BA.5-Targeting-Bivalent-Booster-mRNA-1273.222-Meets-Primary-Endpoint-of-Superiority-Against-Omicron-Variants-Compared-to-Booster-Dose-of-mRNA-1273-in-Phase-23-Clinical-Trial/default.aspx

"Our bivalent boosters also show, in research assays, neutralizing activity [how much?] against BQ.1.1, an increasingly dominant emerging variant, confirming that updated vaccines have the potential to offer protection as the virus continues to evolve rapidly to escape our immunity."

The testing for neutralizing antibodies against BQ.1.1 was in "research assays," presumably because BQ.1.1 is too new for anyone to have developed a validated assay.